These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
328 related articles for article (PubMed ID: 16770314)
21. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? Spaepen K; Stroobants S; Dupont P; Van Steenweghen S; Thomas J; Vandenberghe P; Vanuytsel L; Bormans G; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G J Clin Oncol; 2001 Jan; 19(2):414-9. PubMed ID: 11208833 [TBL] [Abstract][Full Text] [Related]
22. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. Kostakoglu L; Coleman M; Leonard JP; Kuji I; Zoe H; Goldsmith SJ J Nucl Med; 2002 Aug; 43(8):1018-27. PubMed ID: 12163626 [TBL] [Abstract][Full Text] [Related]
23. Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients. Ciammella P; Filippi AR; Simontacchi G; Buglione M; Botto B; Mangoni M; Iotti C; Merli F; Marcheselli L; Bisi G; Ricardi U; Versari A Br J Radiol; 2016; 89(1061):20150983. PubMed ID: 27022777 [TBL] [Abstract][Full Text] [Related]
24. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G Blood; 1999 Jul; 94(2):429-33. PubMed ID: 10397709 [TBL] [Abstract][Full Text] [Related]
25. Staging, response to therapy, and restaging of lymphomas with 18F-FDG PET. Altamirano J; Esparza JR; de la Garza Salazar J; Calvo PS; Vera SR; Chalapud Revelo JR; Estrada G Arch Med Res; 2008 Jan; 39(1):69-77. PubMed ID: 18067998 [TBL] [Abstract][Full Text] [Related]
26. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed? Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905 [TBL] [Abstract][Full Text] [Related]
27. The role of serial pre-transplantation positron emission tomography in predicting progressive disease in relapsed lymphoma. Schot BW; Pruim J; van Imhoff GW; Sluiter WJ; Vaalburg W; Vellenga E Haematologica; 2006 Apr; 91(4):490-5. PubMed ID: 16533726 [TBL] [Abstract][Full Text] [Related]
28. Therapeutic evaluation and prognostic value of interim hybrid PET/CT with (18)F-FDG after three to four cycles of chemotherapy in non-Hodgkin's lymphoma. Zhao J; Qiao W; Wang C; Wang T; Xing Y Hematology; 2007 Oct; 12(5):423-30. PubMed ID: 17852456 [TBL] [Abstract][Full Text] [Related]
29. Prognostic Value of 2-Deoxy-2-[ Dai N; Zhou Y; Deng S; Sang S; Wu Y Contrast Media Mol Imaging; 2021; 2021():5510825. PubMed ID: 33958977 [TBL] [Abstract][Full Text] [Related]
30. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G Haematologica; 2000 Jun; 85(6):613-8. PubMed ID: 10870118 [TBL] [Abstract][Full Text] [Related]
31. Pre-transplant (18)F-fluorodeoxyglucose positron emission tomography-based survival model in patients with aggressive lymphoma undergoing high-dose chemotherapy and autologous SCT. Akhtar S; Al-Sugair AS; Abouzied M; Alkadhi Y; Dingle M; Abdelsalam M; Soudy H; Darwish A; Eltigani A; Elhassan TA; Nabil-Ahmed M; Maghfoor I Bone Marrow Transplant; 2013 Apr; 48(4):551-6. PubMed ID: 22964592 [TBL] [Abstract][Full Text] [Related]
32. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma. Torizuka T; Nakamura F; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Kobayashi M; Ouchi Y Eur J Nucl Med Mol Imaging; 2004 Jan; 31(1):22-8. PubMed ID: 14574514 [TBL] [Abstract][Full Text] [Related]
33. Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Filmont JE; Czernin J; Yap C; Silverman DH; Quon A; Phelps ME; Emmanouilides C Chest; 2003 Aug; 124(2):608-13. PubMed ID: 12907550 [TBL] [Abstract][Full Text] [Related]
34. CT-based texture analysis potentially provides prognostic information complementary to interim fdg-pet for patients with hodgkin's and aggressive non-hodgkin's lymphomas. Ganeshan B; Miles KA; Babikir S; Shortman R; Afaq A; Ardeshna KM; Groves AM; Kayani I Eur Radiol; 2017 Mar; 27(3):1012-1020. PubMed ID: 27380902 [TBL] [Abstract][Full Text] [Related]
35. Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease. Spaepen K; Mortelmans L Q J Nucl Med; 2001 Sep; 45(3):269-73. PubMed ID: 11788819 [TBL] [Abstract][Full Text] [Related]
36. The role of ¹⁸F-fluorodeoxyglucose positron emission tomography at response assessment after autologous stem cell transplantation in T-cell non-Hodgkin's lymphoma patients. Sohn BS; Yoon DH; Kim KP; Kim S; Lee KM; Park JS; Lee DH; Ryu JS; Huh J; Hong IK; Suh C Ann Hematol; 2013 Oct; 92(10):1369-77. PubMed ID: 23689845 [TBL] [Abstract][Full Text] [Related]
37. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection. Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746 [TBL] [Abstract][Full Text] [Related]
39. (18)F-FDG-PET/CT evaluation of response to treatment in lymphoma: when is the optimal time for the first re-evaluation scan? Iagaru A; Wang Y; Mari C; Quon A; Goris ML; Horning S; Gambhir SS Hell J Nucl Med; 2008; 11(3):153-6. PubMed ID: 19081857 [TBL] [Abstract][Full Text] [Related]
40. 18F-FDG PET in malignant lymphoma: significance of positive findings. Castellucci P; Zinzani P; Pourdehnad M; Alinari L; Nanni C; Farsad M; Battista G; Tani M; Stefoni V; Canini R; Monetti N; Rubello D; Alavi A; Franchi R; Fanti S Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):749-56. PubMed ID: 15785956 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]